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Abstract Phosphorylated tau is deposited as insoluble inclusion
bodies in the tauopathies. We have used a new e⁄cient method
to dephosphorylate tau extracted from control and tauopathy
brain. In some tauopathies, including Alzheimer’s disease and
progressive supranuclear palsy, the pattern of insoluble tau iso-
forms re£ected that of soluble tau. In contrast, in corticobasal
degeneration, Pick’s disease, and some forms of fronto-temporal
dementia, speci¢c tau isoforms were selectively sequestered into
insoluble inclusion-forming tau. Therefore the overall expression
of individual tau isoforms does not predict which tau isoforms
are deposited in all tauopathies and di¡erent mechanisms must
operate that result in the deposition of speci¢c tau isoforms.
' 2002 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
Tau protein in human brain exists as a series of six isoforms
generated by alternative splicing from a single gene. Amino-
terminal inserts of 0 (0N), 29 (1N), or 58 (2N) amino acids, in
combination with three (3R) or four (4R) microtubule-binding
repeat regions distinguishes the tau isoforms [1].
The neurodegenerative diseases including Alzheimer’s
disease (AD), Pick’s disease (PiD), progressive supranuclear
palsy (PSP), corticobasal degeneration (CBD) and fronto-tem-
poral dementia with Parkinsonism linked to chromosome 17
(FTDP-17) have been collectively termed the tauopathies due
to the presence of pathological deposits of tau in a¡ected
brain regions. Insoluble tau deposited in AD was found to
di¡er from soluble tau by increased phosphorylation that re-
sulted in reduced electrophoretic mobility of insoluble tau
[2,3]. AD is the best characterised of the tauopathies, and in
this case the paired helical ¢laments (PHF) that form charac-
teristic neuro¢brillary tangles are comprised of insoluble tau
(PHF-tau). On Western blots, PHF-tau appears as three ma-
jor bands and a fourth minor tau species [4]. The di¡erent
patterns of insoluble tau obtained on blots of tauopathy
brains have been suggested to be the result of di¡erential
tau isoform expression [5,6] ; we report here data showing
that this is probably an over-simpli¢cation.
Dephosphorylation of tau with alkaline phosphatase has
been used to show that, compared to soluble tau from control
brain, PHF-tau and insoluble tau from other tauopathies is
abnormally phosphorylated [3,5,7^11]. Dephosphorylation of
PHF-tau using Escherichia coli alkaline phosphatase is cur-
rently the most widely reported method [12]. However, this
method can result in incomplete dephosphorylation of PHF-
tau and poor yield, possibly due to the need for incubation of
solubilised and denatured PHF-tau at elevated temperature.
Bacteriophage lambda protein phosphatase is a dual-speci-
¢city protein serine^threonine and tyrosine phosphatase that
is also active on phosphorylated histidine residues [13,14] and
has been reported to dephosphorylate tau extracted from neu-
roblastoma cells [15]. We found that lambda protein phospha-
tase dephosphorylates soluble and insoluble tau extracted
from tauopathy brain more e⁄ciently than alkaline phospha-
tase. We have used this viral enzyme in combination with a
panel of tau isoform-speci¢c antibodies to investigate phos-
phorylation patterns of individual tau isoforms extracted from
human brain.
2. Materials and methods
2.1. Human brain tissue
Tau was extracted from neurologically and neuropathologically
con¢rmed cases of control, AD, FTDP-17 (+16 intronic and G389R
tau mutations), PiD, PSP and CBD brain. All tissues were taken from
frontal lobe with the exception of PSP (pons) and CBD (amygdala).
Tissue was obtained from the MRC London Neurodegenerative Dis-
eases Brain Bank at the Institute of Psychiatry, King’s College Lon-
don, UK and the Queen Square Brain Bank for Neurological Disor-
ders at the Institute of Neurology, London, UK.
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2.2. Preparation of soluble tau
Human brain tissue was homogenised in 4 vol. 100 mM MES bu¡-
er, pH 6.5, containing 1 M NaCl and complete protease inhibitor
(Roche) and centrifuged at 27 000Ug for 30 min at 4‡C. The super-
natant was centrifuged at 100 000Ug for 1 h at 4‡C, the 100 000Ug
pellet containing insoluble tau was retained (see below) and the
100 000Ug supernatant contained soluble tau. In the case of control
brain, soluble tau was enriched further by heating for 10 min at 100‡C
and centrifuging at 15 000Ug for 30 min at 4‡C. The supernatant,
containing heat-stable soluble proteins, was made to 45% saturation
with ammonium sulphate, maintained in ice for 15 min, and centri-
fuged at 15 000Ug for 30 min at 4‡C. Precipitated proteins were
resuspended in 0.1 vol. (relative to weight of starting brain material)
50 mM Tris^HCl, pH 7.5, and dialysed against the same bu¡er over-
night at 4‡C. The dialysate was clari¢ed by centrifugation at
15 000Ug for 30 min at 4‡C, and the supernatant, containing soluble
heat-stable control brain tau, was retained.
2.3. Preparation of guanidine-solubilised tau
Guanidine-solubilised tau was extracted from the 100 000Ug pellet
of the same brain tissue specimens used for the preparation of soluble
tau as described previously [16]. Guanidine-solubilised tau was dia-
lysed against 50 mM Tris^HCl, pH 7.5, overnight at 4‡C and centri-
fuged at 100 000Ug for 1 h at 4‡C to remove precipitating material.
2.4. Preparation of recombinant human tau
The six isoforms of human tau were expressed individually as re-
combinant proteins in E. coli and puri¢ed as described previously [17].
2.5. Dephosphorylation of tau with lambda protein phosphatase
Human tau preparations in 50 mM Tris^HCl, pH 7.5, were dephos-
phorylated with 20 U/Wl lambda protein phosphatase (New England
Biolabs) for 3 h at 30‡C. Reactions were stopped by the addition of
2U sodium dodecyl sulphate^polyacrylamide gel electrophoresis
(SDS^PAGE) sample bu¡er and heating for 5 min at 100‡C.
2.6. Tau antibodies
TP70 and B19 are polyclonal antibodies recognising all isoforms of
tau [18,19]; RD3 and RD4 are monoclonal antibodies that label tau
isoforms containing three or four microtubule-binding repeats, respec-
tively (de Silva et al., submitted) [20]; BR10 is a rabbit polyclonal
antibody that labels only tau isoforms containing an amino-terminal
insert of 58 residues (2N tau), raised to the peptide C-APGK-
QAAAQPHTEIPEGT, corresponding to residues 84^101 in human
tau (numbering of the largest human tau isoform) with the addition
of an amino-terminal cysteine [21]. The epitopes recognised by the
monoclonal antibodies to tau, Tau.1 and PHF-1, have been described
previously [22,23].
2.7. SDS^PAGE and Western blotting
Tau preparations were resolved on 7.5% or 10% (w/v) polyacryl-
amide gels, electroblotted onto polyvinylidene £uoride or nitrocellu-
lose membranes and probed with antibodies to tau. Blots were devel-
oped using horseradish peroxidase or alkaline phosphatase-conjugated
anti-rabbit or anti-mouse secondary antibodies.
3. Results and discussion
Soluble tau from control human brain is dephosphorylated
readily by lambda protein phosphatase and co-migrates with
the six recombinant human tau isoforms (Fig. 1A, TP70, +).
RD3 and RD4, the antibodies recognising tau with either
three (3R) or four (4R) microtubule-binding repeat domains,
respectively, each labelled di¡erent triplets of dephosphorylat-
ed control brain tau with electrophoretic mobilities co-migrat-
ing precisely with recombinant tau isoforms corresponding to
3R and 4R tau (Fig. 1A, RD3 and RD4, +). RD3 and RD4
strongly labelled the 0N and 1N tau isoforms and more
weakly labelled the 2N tau isoforms, con¢rming the lower
level of expression of 2N tau isoforms in human brain [24].
Surprisingly however, RD3 and RD4 each labelled more than
three bands of untreated control brain tau (Fig. 1A, RD3 and
RD4). RD3 labelled two major bands of untreated soluble
tau, apparently co-migrating with 1N3R and 1N4R tau, as
well as several more di¡use bands, some of which did not
co-migrate with recombinant tau isoforms. RD4 labelled
four bands of approximately equal intensity that did not co-
migrate with the recombinant human tau isoforms. The in-
crease in electrophoretic mobility of soluble tau following de-
phosphorylation was much more marked with RD3 and RD4
than with TP70 labelling as the individual sets of dephosphor-
ylated three- and four-repeat tau isoforms were well discrimi-
nated by the isoform-speci¢c antibodies. The results with RD3
and RD4 show that individual tau isoforms extracted from
post-mortem human brain exist as species with multiple elec-
trophoretic mobilities due to di¡erences in their patterns or
degrees of phosphorylation.
Antibody BR10 is a polyclonal antibody speci¢c for 2N tau
species as shown by the labelling of only the two uppermost
bands in the mixture of all six recombinant human tau iso-
forms (Fig. 1A, BR10, R). Antibody labelling of dephosphor-
ylated soluble tau from adult mouse brain, containing pre-
dominantly 4R tau (Fig. 1B, B19), con¢rms the speci¢city
of BR10 for 2N tau and the lack of labelling of the smaller
1N and 0N tau isoforms by this antibody (Fig. 1B, BR10). In
human brain, BR10 also labels a more di¡use band migrating
close to the position of the smallest tau isoform in human
brain (Fig. 1A, BR10). This species may be a degradation
product of 2N tau as its mobility is slightly increased follow-
ing dephosphorylation and minor degradation products of 4R
tau are visible following dephosphorylation and labelling with
RD4. This species is not due to a cross-reaction of BR10 with
A
TP70 RD3 RD4 BR10 B19        BR10
B
RR
2N4R
2N3R
1N4R
1N3R
0N4R
0N3R
2N4R
1N4R
0N4R
+ + + + + +
Fig. 1. Isoforms of soluble tau in control human brain exist in multiple phosphorylation states. Soluble tau from control human (A) or mouse
(B) brain was untreated or dephosphorylated (+) and proteins were separated on 10% (w/v) SDS^PAGE. Western blots were probed with the
pan-tau antibodies, TP70 or B19, or with the tau isoform-speci¢c antibodies, RD3, RD4, or BR10. Alignment of dephosphorylated tau with
the mixture of recombinant tau isoforms (R) shows the speci¢city of the tau isoform-speci¢c antibodies.
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other tau isoforms as shown by its selective labelling of 2N
tau in the recombinant human tau mixture. Thus, BR10 is
speci¢c for 2N tau isoforms and the minor increase in electro-
phoretic mobility following dephosphorylation of 2N tau,
compared to that of 0N and 1N tau observed with RD3
and RD4, implies that the phosphorylation of 2N tau may
be less heterogeneous or di¡erent to that of the smaller 0N
and 1N tau isoforms.
It has previously been assumed that for soluble tau from
control brain, the six bands observed on Coomassie Blue-
stained polyacrylamide gels and Western blots labelled with
pan-tau antibodies correspond to the six tau isoforms [25^29].
Our results show instead that the tau species visible on gels of
soluble tau from control brain consist of a heterogeneous
mixture of individual tau isoforms in multiple states of phos-
phorylation. Because electrophoresis of untreated tau does not
separate the individual tau isoforms, correct identi¢cation of
the isoform composition of soluble tau therefore requires an
e⁄cient dephosphorylation reaction, followed by labelling
with tau isoform-speci¢c antibodies.
Guanidine-solubilised PHF-tau from AD brain was dephos-
phorylated with lambda protein phosphatase and compared
with untreated PHF-tau. Dephosphorylated PHF-tau labelled
with TP70 appeared as a pattern of six bands with electro-
phoretic mobilities and intensities essentially indistinguishable
from dephosphorylated soluble tau extracted from control
brain (compare Fig. 1, control and Fig. 2, AD, TP70, +).
This result indicates that, in the case of AD, aggregation of
tau does not depend on altered isoform composition but in-
stead particular phosphorylation pro¢les may regulate the
propensity of tau to aggregate into PHF. The overall amount
of PHF-tau immunoreactivity visible on blots following de-
phosphorylation was equal to that of untreated PHF-tau in-
cubated for the same time at the same temperature, indicating
that PHF-tau is not degraded by contaminating proteases
during incubation with this phosphatase. Probing with the
monoclonal antibodies to tau, Tau.1 and PHF-1 showed
that dephosphorylated PHF-tau was labelled by Tau.1, but
not by PHF-1, consistent with the dephosphorylation of tau
at these two epitopes by lambda protein phosphatase (not
shown). Thus, dephosphorylation of PHF-tau by lambda pro-
tein phosphatase is e⁄cient and the recovery of tau is im-
proved, at least in our hands, compared to previously re-
ported methods using E. coli or calf intestinal alkaline
phosphatases [2,3,12].
Antibody RD3 labelled the three lower bands of untreated
PHF-tau that contain the 3R tau isoforms (Fig. 2, RD3) but
not the minor 72-kDa band of PHF-tau faintly labelled by
TP70 (asterisk), as this is comprised of 2N4R tau. After de-
phosphorylation, RD3 labelled a triplet of tau species similar
to that seen in soluble tau from control brain, the uppermost
species, corresponding to 2N3R tau, exhibiting the weakest
labelling (Fig. 2, RD3, +, arrowhead). RD4 labelled the upper
two major bands of untreated PHF-tau as well as the minor
72-kDa species (Fig. 2, RD4, asterisk). Dephosphorylated
PHF-tau resulted in RD4 labelling bands that aligned with
0N4R and 1N4R tau with weak labelling of 2N4R (Fig. 2,
RD4, +, arrowhead). BR10 labelled the upper major band of
untreated PHF-tau and the 72-kDa species (Fig. 2, BR10).
After dephosphorylation BR10 labelled two bands corre-
sponding to 2N3R and 2N4R tau as well as a few minor
degradation products. Probing untreated PHF-tau with tau
isoform-speci¢c antibodies shows that the lower and middle
major bands of PHF-tau contain 3R tau, with a small con-
tribution to the upper major band; the middle and upper
major bands contain 4R tau, with an additional minor band
(72 kDa) running above this, and the upper major and the 72-
kDa band both contain 2N tau. This result con¢rms previous
work from our laboratory identifying the isoform composition
of PHF-tau [17].
Guanidine-solubilised PHF-tau has been dephosphorylated
successfully using E. coli alkaline phosphatase at 67‡C [12] ;
however, at least in our hands, this method often results in
poor yields, possibly due to the activity of contaminating
proteases and the increased temperature. We have found pre-
viously that the speci¢c activity of E. coli and calf intestinal
phosphatases and relative resistance of PHF-tau to dephos-
phorylation is such that signi¢cant amounts of phosphatase
protein are required and these are present on gels following
electrophoresis. These phosphatases have similar electropho-
retic mobilities to untreated PHF-tau (calf intestinal phospha-
tase) and dephosphorylated tau (E. coli phosphatase) and thus
they interfere with the resolution of tau species. It has proved
di⁄cult therefore to obtain well-resolved bands of untreated
and dephosphorylated PHF-tau treated with these two phos-
phatases. However, using lambda protein phosphatase, de-
phosphorylated PHF-tau is obtained in good yield and ap-
pears to be dephosphorylated e⁄ciently using the conditions
described. Furthermore, lambda protein phosphatase (25
kDa) on gels does not interfere with the tau pattern obtained
after dephosphorylation. The degree of dephosphorylation of
PHF-tau achieved following incubation with lambda protein
phosphatase appears to be comparable to that of hydrogen
£uoride treatment [8]. Since hydrogen £uoride is a hazardous
reagent that cannot be used routinely in many laboratories,
dephosphorylation of tau by lambda protein phosphatase rep-
resents a signi¢cant improvement on methods in current use.
Lambda protein phosphatase has been used previously to de-
phosphorylate tau in extracts from a neuroblastoma cell line
but, to our knowledge this is the ¢rst report of this enzyme
being used to dephosphorylate tau extracted from human
brain [15]. The successful dephosphorylation by lambda pro-
tein phosphatase of guanidine-solubilised tau suggests that
this enzyme might also be used to dephosphorylate other pro-
teins that are relatively resistant to alkaline phosphatases.
Lambda protein phosphatase dephosphorylated tau from
the di¡erent tauopathies and the isoform composition of solu-
ble and guanidine-solubilised fractions in these brains was
+ + + +
TP70 RD3 RD4 BR10
2N4R
2N3R
1N4R
1N3R
0N4R
0N3R
Fig. 2. Dephosphorylation of PHF-tau with lambda protein phos-
phatase. PHF-tau from AD was dephosphorylated (+), separated on
10% (w/v) SDS^PAGE and blots were probed with tau antibodies,
TP70, RD3, RD4 or BR10. Asterisks indicate the minor PHF-tau
isoform which is di⁄cult to discern. Arrowheads indicate the weak
bands labelled by RD3 and RD4 after dephosphorylation of PHF-
tau. The positions of the four PHF-tau bands are indicated on the
left and the six recombinant human tau isoforms on the right.
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compared (representative cases in Fig. 3). We found that none
of the tauopathy cases examined showed guanidine-solubilised
tau consisting exclusively of either 3R or 4R tau isoforms,
consistent with recent reports [10,30] and con£icting with pre-
vious studies on untreated insoluble tau [31,32]. AD tau con-
tained all six isoforms and there was no di¡erence in patterns
between soluble and guanidine-solubilised fractions (Fig. 3,
AD). Guanidine-solubilised tau from CBD brain consisted
predominantly of 0N4R with a lesser amount of 1N4R tau
and negligible amounts of the other tau isoforms (Fig. 3,
CBD). This was in contrast to soluble CBD tau that appeared
to contain slightly more 0N4R tau but otherwise similar tau
isoform ratios to control brain. PiD showed a soluble tau
pattern that was similar to that of control brain, with a slight
reduction in 0N3R tau, whereas the guanidine-solubilised
fraction of PiD contained increased 3R isoforms (Fig. 3,
PiD). This ¢nding implicates primarily 1N3R tau, as well as
lesser amounts of 0N3R, 1N4R, and 2N3R tau in the forma-
tion of tau-positive Pick bodies and con¢rms recent reports of
4R tau in PiD [11,33]. Soluble FTDP-17 (G389R) tau did not
contain increased 4R tau despite the guanidine-solubilised tau
from this brain having a marked increase in 0N4R tau, where-
as tau from FTDP-17 (+16) brain exhibited an increased
4R/3R tau ratio in both soluble and guanidine-solubilised
fractions (Fig. 3, FTDP lanes). Soluble and guanidine-solubi-
lised tau from PSP brain gave similar isoform patterns after
dephosphorylation, with a predominance of 1N3R and 1N4R
isoforms, and a reduced amount of 0N3R tau, but no overall
increase in 4R tau isoforms (Fig. 3, PSP). The consistent
¢nding of reduced or absent 0N3R tau in PSP is interesting
and mirrors a previous report in CBD [34], however, we found
di¡erences in the overall compositions of the tau isoforms in
PSP and CBD.
Therefore only in CBD and FTDP-17(+16) did we detect
overt alterations of soluble tau isoform expression that were
re£ected in guanidine-solubilised tau. It appears that, at least
in the brain regions examined here, there may be sequestra-
tion of speci¢c tau isoforms into insoluble (and hence inclu-
sion-forming) tau in CBD, PiD and FTDP-17, but in AD and
PSP such a selective sequestration may not occur. Therefore,
further work is required to identify the mechanisms giving rise
to the deposition of tau inclusions in the tauopathies, such
mechanisms may include subtle changes in isoform expres-
sion, post-translational modi¢cation, and/or selective incorpo-
ration of isoforms into insoluble tau.
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